Wegovy 7.2mg dose approval: what changed and what it means in practice

Step 1: How the MHRA reached the 7.2mg decision

The path to 7.2mg approval unfolded in two stages. In January 2026, the MHRA authorised the 7.2mg dose itself, at that point administered as three separate 2.4mg Wegovy pens in a single week, an arrangement that worked clinically but was cumbersome in practice. Novo Nordisk had already developed a dedicated device designed to deliver the full 7.2mg in a single injection, and on 14 April 2026 the MHRA confirmed approval of that pen for adults with obesity.

The supporting evidence drew on a broader clinical programme showing that pushing the maintenance dose above 2.4mg produced meaningfully greater average weight loss. Trials reported roughly 20.7% average body-weight reduction over 72 weeks at 7.2mg. For context, the earlier 2.4mg maintenance dose produced around 15% average loss in the STEP 1 trial published in the New England Journal of Medicine. That gap matters clinically, because the difference between doses can determine whether someone reaches a threshold that changes their cardiovascular or metabolic risk. The MHRA's announcement on 14 April 2026 confirmed the pen's approval and set out the patient population it applies to.

You can read a fuller breakdown of the overall semaglutide dose schedule on the Wegovy doses overview, which covers all steps from 0.25mg through to 7.2mg.

Step 2: What the new pen actually is

The 7.2mg Wegovy pen is a pre-filled, single-dose auto-injection device. Unlike the original Wegovy pens, which require the user to dial a dose, this device comes pre-set: insert, press, done. A built-in covered needle activates on use and locks permanently afterwards, reducing the risk of needlestick injury. The pen is used once weekly, on the same day each week, injected into the abdomen, thigh, or upper arm, rotating the site each time.

Storage follows the standard Wegovy cold-chain requirement: refrigerated at 2–8°C until use. Because it is a prescription-only medicine, a pen does not simply arrive on your doorstep; it is dispensed by a GPhC-registered pharmacy following a clinical assessment and a valid prescription. When it does arrive (via a tracked DPD delivery in plain, unbranded packaging) the pen itself is pre-loaded and ready; there is no assembly required before your first injection.

For specific questions about side effects at this dose level, the 7.2mg side-effect profile page covers what the trial data showed and what to watch for after a dose increase. If you are curious how early-adopter patients have found the experience, the Wegovy 7.2mg reviews page compiles relevant published patient-reported data.

Step 3: Who the 7.2mg approval applies to

The MHRA's April 2026 approval is specific. The 7.2mg dose is licensed for adults with a BMI of 30 or above for weight management. It does not extend downward to the 27–29.9 BMI range that the lower Wegovy doses cover with a qualifying comorbidity, and it applies to weight management only, not to the separate cardiovascular or MASH indications that semaglutide also holds. Lower BMI thresholds apply for certain ethnic backgrounds under UK clinical guidance, so the prescriber will work through these details during assessment.

Critically, nobody starts at 7.2mg. The titration schedule begins at 0.25mg, moving upward in roughly four-weekly steps as tolerated, through 0.5mg, 1mg, 1.7mg and 2.4mg before reaching 7.2mg. A prescriber reviews the picture at each stage. If less than 5% of body weight has been lost after six months at the highest tolerated dose, continuing treatment is formally reviewed. This staged approach matters for safety: the gastrointestinal side effects that are most common with semaglutide (nausea, loose stools, reduced appetite) tend to be most noticeable in the first weeks at any new dose level and typically ease as the body adjusts.

The Wegovy treatment overview sets out the full eligibility picture, including how private treatment compares with NHS access routes. If you want to understand how the cost of treatment at higher doses fits into the broader private market, the Wegovy price comparison page gives an honest UK context.

Step 4: How to access 7.2mg Wegovy through a regulated route

Wegovy at any dose is a prescription-only medicine. The only legal route to obtaining it is through a prescriber who has assessed your eligibility, reviewing your weight, BMI, medical history, and any medicines you already take. There is no legitimate shortcut. Online sellers offering GLP-1 medicines at prices well below the market rate, or without requiring any clinical assessment, are a serious red flag; the MHRA has warned publicly about counterfeit and illegally traded weight-loss pens, and fake products have caused real harm.

To verify that any online pharmacy is genuine, check it against the GPhC register at pharmacyregulation.org, every regulated UK pharmacy has a premises registration number listed there. At nume, our GPhC-registered Independent Prescribers review consultations personally. If 7.2mg becomes relevant at your stage of treatment, that conversation happens with a real clinician, not automated software. Availability of specific dose formats is confirmed during consultation. The MHRA's approval of the higher 7.2mg Wegovy dose is covered in more detail alongside the regulatory background, and our weight-loss treatment overview explains how different options sit alongside one another. If you are ready to find out whether Wegovy is clinically suitable for you, a free consultation with our prescribers is the right place to start.